Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:03 31/05/2024 BST			5-day change	1st Jan Change
15.04 ^USD	-1.38%		-2.97%	+213.33%

05-24	Novavax awaits FDA decision on whether its next COVID shot can be offered in US	RE
05-23	Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024	CI

Novavax : Australia enters agreement to buy 51 mln doses of Novavax's COVID-19 vaccine

January 07, 2021 at 10:45 pm

Jan 7 (Reuters) - The government of Australia has signed an advanced agreement to purchase 51 million doses of Novavax Inc's experimental COVID-19 vaccine, the company disclosed in a regulatory filing on Thursday. (https://bit.ly/35BGW3Z) (Reporting by Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)

Latest news about Novavax, Inc.

Novavax awaits FDA decision on whether its next COVID shot can be offered in US	05-24	RE
Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024	05-23	CI
B. Riley Boosts Price Target on Novavax to $29 From $11, Maintains Buy Rating	05-23	MT
Novavax: 1st shipment of R21/MatrixM malaria vaccine	05-21	CF
Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft...	05-20
Focus on Nvidia	05-20
Shah Capital ends campaign against Novavax board after Sanofi deal	05-20	RE
Novavax Stockholder Shah Capital Withdraws Campaign Against Reelection of Directors	05-20	MT
Shah Capital withdraws campaign against Novavax directors after Sanofi deal	05-20	RE
Shah Capital withdraws campaign against three Novavax directors	05-20	RE
Shah Capital Management Announces Withdrawal of Nominations	05-20	CI
Transcript : Novavax, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM	05-15
Global markets live: Apple, Sony, Vodafone, Booking, Walmart...	05-14
Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Tuesday; AMC Entertainment, GameStop to Advance	05-14	MT
Novavax Shares Pop Another 50% Following Sanofi Deal	05-13	DJ
Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...	05-13
Wall Street closes up ahead of inflation data	05-10	RE
News Highlights : Top Company News of the Day - Friday at 5 PM ET	05-10	DJ
News Highlights : Top Company News of the Day - Friday at 7 PM ET	05-10	DJ
Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup	05-10	DJ
US Equity Markets Close Mixed Friday After Consumer Sentiment Falls	05-10	MT
Sector Update: Health Care Stocks Higher Late Afternoon	05-10	MT
News Highlights : Top Company News of the Day - Friday at 3 PM ET	05-10	DJ
Novavax shares soar on license deal with Sanofi	05-10	RE
Novavax Surges on $1.2 Billion Sanofi Vaccine Deal	05-10	MT

Chart Novavax, Inc.

Duration

Period

More charts

Company Profile

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Sector

Biotechnology & Medical Research

Calendar

06/06/2024 - Jefferies Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novavax Surges on $1.2 Billion Sanofi Vaccine Deal

May 10, 2024 at 07:52 pm

More Strategies

Ratings for Novavax, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.03 USD

Average target price

21.6 USD

Spread / Average Target

+43.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NOVAVAX, INC.	+213.33%	2.11B
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research